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Introduction 
 
The number of patients diagnosed with Chronic Kidney Disease (CKD) is increasing, 
with recent studies suggesting over 10% of the population may have CKD (1;2). This 
high prevalence is due to a variety of factors. A major contributor, in developed 
countries, is the increasing age of the population; epidemiological studies show that the 
prevalence of CKD increases dramatically with advancing age (2). As the population 
lives longer and the proportion of older people increases, so the prevalence of CKD 
increases. In addition, use of estimated glomerular filtration rate (eGFR) has contributed 
to increased recognition of CKD (3). Improved accessibility to renal services has also 
meant that many patients previously not referred are now being seen by nephrologists. 
 
The presence of CKD has many implications for the patient, including increased 
morbidity and all cause mortality, in particular increased risk of death from 
cardiovascular disease (4). The majority of patients with CKD will die of a non-renal 
cause, and although their renal disease may contribute, it is not directly responsible. A 
proportion of the CKD population will progress to Stage 5 CKD and need renal 
replacement therapy, either dialysis or renal transplantation. But even with optimal renal 
replacement therapy, the life expectancy for patients with Stage 5 CKD is significantly 
reduced compared to healthy populations. In the presence of advanced age and significant 
co-morbidity, prognosis may be short (5). In addition, a growing number of patients are 
opting not to have dialysis (6). 
 
Irrespective of dialysis decision, most of these patients will die under the care of a 
nephrologist. It is critical therefore that we understand this phase of patient management, 
not only to provide optimal care for individuals, but to aid the planning of services to 
support patients in the terminal phase of their disease. 
 
Disease trajectories 
 
The concept of distinct patterns of functional decline over time leading to death is well 
established in palliative care (7). Four distinct trajectories have been described (Figure 1) 
(8;9). Firstly, sudden death can occur at any stage without a prior diagnosis or symptoms 
of underlying disease (Figure 1A). Secondly, after the diagnosis of a terminal illness, 
there is preservation of function followed by a rapid decline in the advanced stages 
(Figure 1B), typical of a patient with cancer. The third pattern is one of acute episodes, 
frequently requiring hospital admission, and often without recovery to the previous level 
of function (Figure 1C). Eventually, death occurs during one of these acute episodes. This 
pattern is typical of patients with organ failure, such as end stage cardiac or respiratory 
disease. The final pattern is one of gradual decline in already poor function prior to death 
and is typically seen in the very elderly and those patients with diseases such as dementia 
(Figure 1D). 
 
Implications of disease trajectories 
 
For patients with advanced renal disease and their families, and for medical professionals 
planning and delivering their care, it is vital to understand disease trajectories towards the 
end of life, and becoming increasingly important for nephrologists to consider as the age 
and co-morbidity of the advanced renal population increases. 
 
First, many patients will want to know their prognosis (10). Questions frequently asked 
by patients include: How long do I have to live? What will happen at the end? The 
answers to these questions will inform the patient’s expectations for the future and may 
influence their choice of treatment. Nephrologists need more evidence about survival 
times (5), but also better insights into the most likely course or trajectory of illness the 
patient might expect (11), so as to best advise patients as end of life nears. Sensitive end 
of life discussions help patients maintain hope and realistic expectations, rather than 
removing hope, as professionals often expect (12). Evidence also shows that, alongside 
good symptom control, patients give high priority to the opportunity to prepare for death 
(13;14). 
 
Second, an understanding of trajectories is needed to underpin service provision. Not 
only functional trajectories, but symptoms and other components of disease trajectories 
need to be mapped. Predictors of change in functional or symptom trajectories also need 
to be determined. Knowing when patients are likely to experience rapid functional 
decline, high symptom burden, and become most dependent on health and social services 
has major implications for the planning and delivery of their care. 
 
Trajectories in renal disease 
 
Is it appropriate to extrapolate disease trajectories developed in other end-of-life 
populations to renal patients? There are aspects of renal disease, in particular the 
availability of dialysis, which differentiate renal failure from other end-stage disease, and 
it is likely that the functional trajectories of patients with advanced renal disease will 
vary, largely according to whether dialysis is undertaken, and according to the presence 
or absence of co-morbid conditions. 
 
Some will follow functional trajectories similar to end stage cardiac or respiratory disease 
(Figure 1C), since renal patients often have similar recurrent acute episodes, such as 
cardiovascular events, infective episodes, or problems with fluid overload. Dialysis 
patients may have specific acute episodes relating to dialysis access. After each acute 
episode, patients are left with greater functional deficit or increased problems with the 
ongoing delivery of dialysis. These episodes become increasingly frequent and refractory 
to treatment as the patient nears the end of life. Recognition of this pattern enables those 
at risk of imminent death to be managed more appropriately, and to have the chance that 
most (but not all) patients prefer, to plan and prepare for death, together with their 
families. 
 
The trajectory of sudden death (Figure 1A) may occur for some renal patients, most 
commonly due to a cardiovascular event, although even for these patients, preceding 
events may have heralded decline. Withdrawal from dialysis is increasingly frequent 
cause of death among the dialysis population; those who withdraw from dialysis likely 
have a much shorter period of decline in their illness trajectory, closer to the pattern 
described for malignant disease (Figure 1B). However, many patients who withdraw 
from dialysis experience considerable functional decline well before withdrawal, and 
some may follow the more episodic trajectory (Figure 1C). 
 
Conservatively managed patients can remain stable for long periods of time with a rapid 
decline in the late stages of their disease. This decline can be difficult to predict and 
without obvious precipitant. Services need to react rapidly to respond to such abrupt 
change in patient needs. A slower decline in function may be seen in other conservatively 
managed patients (15), with increasing frailty and dependence over several months prior 
to death. These patients may be very symptomatic during this period (16), needing good 
symptom control as well as psychological and social support for optimal outcomes. For 
this group, knowledge of the trajectory; how the disease will progress, what to expect, 
and provision of adequate community support may prevent inappropriate and expensive 
hospital admissions. 
 
Summary 
 
With increasing numbers of patients reaching Stage 5 CKD, it is vital that we understand 
the terminal phases of renal failure. The concept of disease trajectories provides a useful 
way to do this. Care for the renal patient in the last months of life has received much less 
attention than many other areas of nephrology. Yet this phase of illness needs equal 
levels of attention if we are to ensure good quality of death for all (17). 
 
Collaboration between nephrology and palliative care provides the best chance for rapid 
improvements in care. The data available on disease trajectories is one example of the 
useful cross-fertilisation between these specialities that can inform both patients and 
health care professionals, and allow us to improve quality of care. Although there is little 
evidence available as yet on trajectories in the renal population, the disease trajectories 
developed in other end of life populations are a useful way of conceptualising and 
understanding care in the last months and weeks of life, to provide a basis for further 
research, and rapidly identify ways to improve care towards the end of life. 
 
Figure Legend 
 
Figure 1. The typical disease trajectories identified in patients with different diseases. 
From Lunney et al 2002 (8). 
Figure 1 
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